March 19, 2013
/PRNewswire/ -- Aviir Inc., a biotechnology company dedicated to enhanced detection and prevention of cardiovascular disease through innovative diagnostic tests, announced that
, MD, Clinical Professor of Pathology at
and Aviir Inc. CEO, addressed a select group of physicians and leading cardiologists on the
Latest Advances in Cardiovascular Risk Assessment
at a special invitation-only reception in
The event took place
, during the American College of Cardiology (ACC) 2013 Annual Conference and included guest speakers
, PhD, Professor of Cardiovascular Medicine from the
School of Medicine, and
, MD, Cardiologist at Cedars-Sinai Medical Center.
"Our goal is to present and discuss the best cardiac risk assessment methods available. Presenting next generation tests like MIRISK VP
with fellow physicians in an intimate forum enabled a free exchange and the chance to discuss advances in the field of preventative cardiology," said Dr. Harrington.
Many physicians at the event elected to take the MIRISK VP test on-site, which was offered by GUARDaHEART, a national non-profit dedicated to heart disease awareness and prevention.
MIRISK VP stratifies the intermediate risk group, which has proven to be a critical part of risk assessment, as most adverse cardiac events happen to intermediate risk individuals. In fact, MIRISK VP was shown in a peer-reviewed publication to significantly improve cardiac risk assessment by reclassifying intermediate risk individuals to either high or low risk groups, resulting in a net reclassification index of 43% compared to the standard Framingham method.
"As a cardiologist, I am excited about the prospect of this test. I understand its value to my patients and practice and I was happy to speak to my colleagues about its usefulness in the clinic," stated Dr. Simonini.